This website uses cookies to improve your experience. Learn more about cookies and how to manage them.

BPS LIVE: Webinar 2: Psychedelics; Preclinical trials and translatability

This three-part webinar series aims to address the drug discovery process of rapid acting antidepressants both pre-clinically and clinically. Taking ketamine as a first example and moving on to examine the rapidly expanding field of psychedelic research, issues around translatability with ketamine as a reference point to compare similarities and differences. Finally, we will look to the future and where things are likely to be in the coming years.

17 May 2022

Abstracts deadline:

Registration deadline:

Online - View map

  • Overview

Register now

Part of the BPS LIVE: Rapid acting antidepressants: From ketamine to psychedelics series

This three-part webinar series aims to address the drug discovery process of rapid acting antidepressants both pre-clinically and clinically. Taking ketamine as a first example and moving on to examine the rapidly expanding field of psychedelic research, issues around translatability with ketamine as a reference point to compare similarities and differences. Finally, we will look to the future and where things are likely to be in the coming years.

Given the recent increase in interest for psychedelic based research to use as a treatment for various therapeutic areas, including neuropsychiatric and CNS disorders, we intend this webinar series to be of interest to new drug developers who are looking to break into this space. It will also be a very valuable for those already established in theses these fields and would like to further explore the regulatory and data requirements within the preclinical and clinical settings to progress drug development.

In this second webinar of the series we will cover:

  • Pitfalls and translatability in animal models of psychiatric disorders
  • Pitfalls and translatability in psychedelic research
  • Can we model the psychedelic experience and is that necessary?